Akademik Veri Yönetim Sistemi
NUCLEAR ENGINEERING AND TECHNOLOGY, sa.104155, ss.1-11, 2026 (SCI-Expanded, Scopus)
prostate phantom for its potential use in prostate brachytherapy. The line 142Pr sources containing in capillary
glass tubes, were produced through 141Pr(n,γ)142Pr reaction at a thermal neutron flux of 2.5x1012 n·cm−2·s−1 in a
250 kW Triga Mark II research reactor. Each tube containing ∼100 mg 141Pr (100%), when irradiated for 25 min,
resulted in a dose rate of ∼2 Gy/h suitable for brachytherapy, even after a decay time of 10–12 h. Dosimetric
characterization of line 142Pr sources were performed in terms of source strength, non-uniformity and active source
length according to NCS-14, ICRU-72, and AAPM TG-60/TG-149 protocols by using EBT3 radiochromic film and
ExradinW1 plastic scintillator detector(PSD). Measurements were conducted both in free-air and in waterequivalent
solid phantoms, followed by dose mapping in a patient-specific, 3D printed anthropomorphic pelvic
phantom representing prostate (target), bladder, and rectum (organs-at-risk). Although it does not exactly represent
a brachytherapy treatment case, the dosimetric results indicate that line 142Pr sources can be used in
brachytherapy applications at least as a medium-dose-rate brachytherapy source.
The produced novel line 142Pr beta sources exhibited low dose non-uniformities (0.8–3.7%) and source
strengths of approx. 2–3 Gy/h at 10 h post-production. Dose profiles obtained on the prostate phantom indicated
a steep beta dose fall-off and favorable dose distributions at OARs. The overall results indicate that line 142Pr beta
sources meet the essential dosimetric requirements for brachytherapy sources, and it may serve as a promising
candidate for future interstitial prostate applications, pending further pre-clinical evaluation.